<SEC-DOCUMENT>0001171843-21-003078.txt : 20210504
<SEC-HEADER>0001171843-21-003078.hdr.sgml : 20210504
<ACCEPTANCE-DATETIME>20210504060508
ACCESSION NUMBER:		0001171843-21-003078
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20210504
FILED AS OF DATE:		20210504
DATE AS OF CHANGE:		20210504

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Innate Pharma SA
		CENTRAL INDEX KEY:			0001598599
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			I0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39084
		FILM NUMBER:		21885851

	BUSINESS ADDRESS:	
		STREET 1:		117 AVENUE DE LUMINY
		STREET 2:		BP 30191
		CITY:			MARSEILLE
		STATE:			I0
		ZIP:			13009
		BUSINESS PHONE:		33430303030

	MAIL ADDRESS:	
		STREET 1:		117 AVENUE DE LUMINY
		STREET 2:		BP 30191
		CITY:			MARSEILLE
		STATE:			I0
		ZIP:			13009

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Innate Pharma, SA
		DATE OF NAME CHANGE:	20140129
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>f6k_050421.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<html><head><title></title></head><body style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><div align="center"><div style="margin-top: 3pt; margin-bottom: 12pt;"><div style="font-size: 1pt; border-top: Black 2.5pt solid; border-bottom: Black 1.1pt solid; width: 100%;">&#160;</div></div><p style="font-size: 14pt;" align="center"><strong>UNITED STATES</strong><br /><strong>SECURITIES AND EXCHANGE COMMISSION</strong><br /><strong>Washington, D.C. 20549</strong></p><p style="font-size: 14pt; text-transform: uppercase;" align="center"><strong>Form 6-K</strong></p><p style="text-align: center;"><strong></strong></p><p style="text-align: center;"><strong>REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934</strong></p><p style="text-align: center;"><strong>Date of report:&#160;</strong><strong>For the month of May 2021</strong></p><p style="text-align: center;"><strong>Commission File Number: 001-39084</strong></p><p style="text-align: center;"><font style="font-size: 12pt;"><strong>Innate Pharma S.A.</strong></font><br />(Translation of registrant's name into English)</p><p style="text-align: center;"><strong>Innate Pharma S.A.<br />117 Avenue de Luminy&#8212;BP 30191<br />13009 Marseille, France <br />+ 33 (0) 4 30 30 30 &#160;</strong><br />(Address of principal executive office)</p></div><p>Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.</p><p>Form 20-F [&#160;X ] &#160;&#160;&#160;&#160;&#160;Form 40-F [&#160;&#160; ]</p><p>Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): </p><p>Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): </p><hr style="page-break-after: always;" noshade="noshade" /><p> <p style="text-align: center; font-size: 10pt; font-weight: bold;">EXHIBIT INDEX&#160;</p><table style="font-size: 10pt;" border="0" cellspacing="0" cellpadding="0"><tr><td style="font-size: 10pt; font-weight: bold; text-decoration: underline;" valign="bottom">Exhibit</td><td style="font-size: 10pt; width: 20px;">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-decoration: underline;" valign="bottom">Description</td></tr><tr><td style="font-size: 10pt;">&#160;</td><td style="font-size: 10pt; width: 20px;">&#160;</td><td style="font-size: 10pt;">&#160;</td></tr><tr><td style="font-size: 10pt;"><a href="exh_991.htm">99.1</a></td><td style="font-size: 10pt; width: 20px;">&#160;</td><td style="font-size: 10pt;"><a href="exh_991.htm">Press Release dated May 4, 2021</a></td></tr></table></p><p /><hr style="page-break-after: always;" noshade="noshade" /><p style="text-align: center;"><strong>SIGNATURES</strong></p><p>Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</p><table style="font-family: Times New Roman; font-size: 10pt;" border="0" width="100%" cellspacing="0" cellpadding="0"><tr valign="top"><td>&#160;</td><td>&#160;</td><td style="text-transform: uppercase;" colspan="2"><strong>Innate Pharma S.A.</strong></td></tr><tr valign="top"><td style="width: 47%;">&#160;</td><td style="width: 6%;">&#160;</td><td style="text-align: center; width: 10%;">&#160;</td><td style="text-align: center; width: 84%;">&#160;</td></tr><tr valign="top"><td>&#160;</td><td>&#160;</td><td colspan="2"></td></tr><tr valign="top"><td>Date: May 4, 2021</td><td>&#160;</td><td>By:</td><td style="border-bottom: black 1pt solid;">/s/ Laure-H&#233;l&#232;ne Mercier&#160;&#160;&#160;&#160;</td></tr><tr valign="top"><td>&#160;</td><td>&#160;</td><td>Name:&#160;&#160;&#160;&#160;&#160;</td><td>Laure-H&#233;l&#232;ne Mercier</td></tr><tr valign="top"><td>&#160;</td><td>&#160;</td><td>Title:</td><td>Chief Financial Officer</td></tr><tr valign="top"><td>&#160;</td><td>&#160;</td><td colspan="2"></td></tr></table></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exh_991.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN"><html lang="en-US"><head><title>EdgarFiling</title><meta content="text/html; charset=windows-1252" ><meta name="GENERATOR" content="MSHTML 8.00.7601.18094" ></head><body bgcolor="#ffffff"><p style="text-align: right;"><strong>EXHIBIT 99.1</strong></p><p style="text-align: center;"><font style="font-size: 14pt;"><strong>Innate Pharma Announces Conference Call and Webcast for 2021 First Quarter Business Update</strong></font></p><p style="text-align: center;"><strong></strong></p><p>
 <p align="justify">MARSEILLE, France, May  04, 2021  (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris: IPH &#8211; ISIN: FR0010331421; Nasdaq: IPHA) (&#8220;<strong>Innate</strong>&#8221; or the &#8220;<strong>Company</strong>&#8221;), today announced that the Company will hold a conference call on Thursday, May&#160;11, 2021 at 3 p.m. CEST / 9 a.m. ET, to give an update on business progress during the first quarter of 2021.<br ></p>  <p align="justify">Participating in the call will be Innate Pharma&#8217;s Chief Executive Officer Mondher Mahjoubi, MD, Chief Medical Officer Joyson Karakunnel, MD, MSc, FACP, and Chief Financial Officer Fr&#233;d&#233;ric Lombard, MBA.</p>  <p align="justify"><strong><u>Details for the Virtual Event</u></strong></p>  <p align="center">The live webcast will be available at the following link: <br > <u>https://edge.media-server.com/mmc/p/o65bcx4w</u></p>  <p align="start">Participants may also join via telephone to ask questions by registering in advance of the event at <u>http://emea.directeventreg.com/registration/1570429</u>. Upon registration, participants will be provided with dial-in numbers, a direct event passcode and a unique registrant ID that they may use 10 minutes prior to the event start to access the call. Call reminders will also be sent to registered participants via e-mail the day prior to the event.</p>  <p align="justify">This information can also be found on the Investors section of the Innate Pharma website, <u>www.innate-pharma.com</u>. A replay of the webcast will be available on the Company website for 90 days following the event.</p>  <p align="justify"><strong>About Innate Pharma:</strong></p>  <p align="justify">Innate Pharma S.A. is a global, clinical-stage oncology-focused biotech company dedicated to improving treatment and clinical outcomes for patients through therapeutic antibodies that harness the immune system to fight cancer.</p>  <p align="justify">Innate Pharma&#8217;s broad pipeline of antibodies includes several potentially first-in-class clinical and preclinical candidates in cancers with high unmet medical need.</p>  <p align="justify">Innate has been a pioneer in the understanding of natural killer cell biology and has expanded its expertise in the tumor microenvironment and tumor-antigens, as well as antibody engineering. This innovative approach has resulted in a diversified proprietary portfolio and major alliances with leaders in the biopharmaceutical industry including Bristol-Myers Squibb, Novo Nordisk A/S, Sanofi, and a multi-products collaboration with AstraZeneca.</p>  <p align="justify">Headquartered in Marseille, France, with a US office in Rockville, MD, Innate Pharma is listed on Euronext Paris and Nasdaq in the US.</p>  <p align="justify">Learn more about Innate Pharma at <u>www.innate-pharma.com</u></p>  <p align="justify"><strong>Information about Innate Pharma shares:</strong></p> <table style="width:853px; border-collapse:collapse !important;;border-collapse: collapse; "><tr><td style="text-align: left ;  vertical-align: middle; "><strong>ISIN code</strong> <br ><br > <strong>Ticker code</strong> <br ><br > <strong>LEI</strong></td><td style="text-align: left ;  vertical-align: middle; ">FR0010331421 <br ><br > Euronext: IPH Nasdaq: IPHA <br ><br > 9695002Y8420ZB8HJE29</td></tr></table> <p align="justify"><strong>Disclaimer:</strong></p>  <p align="justify">This press release contains certain forward-looking statements, including those within the meaning of the Private Securities Litigation Reform Act of 1995. The use of certain words, including &#8220;believe,&#8221; &#8220;potential,&#8221; &#8220;expect&#8221; and &#8220;will&#8221; and similar expressions, is intended to identify forward-looking statements. Although the company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. These risks and uncertainties include, among other things, the uncertainties inherent in research and development, including related to safety, progression of and results from its ongoing and planned clinical trials and preclinical studies, review and approvals by regulatory authorities of its product candidates, the Company&#8217;s commercialization efforts, the Company&#8217;s continued ability to raise capital to fund its development and the overall impact of the COVID-19 outbreak on the global healthcare system as well as the Company&#8217;s business, financial condition and results of operations. For an additional discussion of risks and uncertainties which could cause the company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors (&#8220;Facteurs de Risque") section of the Universal Registration Document filed with the French Financial Markets Authority (&#8220;AMF&#8221;), which is available on the AMF website http://www.amf-france.org or on Innate Pharma&#8217;s website, and public filings and reports filed with the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;), including the Company&#8217;s Annual Report on Form 20-F for the year ended December 31, 2020, and subsequent filings and reports filed with the AMF or SEC, or otherwise made public, by the Company.</p>  <p align="justify">This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.</p>  <p align="justify"><strong>For additional information, please contact:</strong></p> <table style="width:904px; border-collapse:collapse !important;;border-collapse: collapse; "><tr><td style="vertical-align: top ; "><strong><u>Investors</u></strong><br ><br > <strong>Innate Pharma</strong><br ><br > Tel.: +33 (0)4 30 30 30 30 <br ><br > <u>investors@innate-pharma.com</u> <br ><br > <br ><br ></td><td style="text-align: justify ;  vertical-align: middle; "><strong><u>Media</u></strong> <br ><br > <strong>Innate Pharma</strong> <br ><br > Tracy Rossin (Global/US) <br ><br > Tel.: +1 240 801 0076 <br ><br > <u>Tracy.Rossin@innate-pharma.com</u> <br ><br > <br ><br > <strong>ATCG Press </strong> <br ><br > Marie Puvieux (France) <br ><br > Tel.: +33 (0)9 81 87 46 72 <br ><br > <u>in</u><u>nate-pharm</u><u>a@atcg-partners.com</u></td></tr></table></p><p ></p></body></html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
